Grant H. Skrepnek, Ph.D., R.Ph.

Associate Professor

Department of Pharmacy: Clinical and Administrative Sciences

Phone (405) 271-6878 x47105

Fax (4050 271-6430

Office CPB 214

Email grant-skrepnek@ouhsc.edu


Summary

I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.



Research

Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.




Education & Experience

Ph.D. in Pharmacy Administration

University of Texas at Austin, Austin, TX

Dissertation: Stock market valuation and firm-level determinants of innovative activity in the pharmaceutical industry.


2002

M.S. in Pharmacy Administration

University of Texas at Austin, Austin, TX

Thesis: The effect of merger and acquisition activity on shareholder returns in the pharmaceutical industry.


1998

B.S. in Pharmacy Business Management

University of Texas at Austin, Austin, TX

1994


Publications & Presentations

1 2 3 4 > >>
  1. Tieu J D, Williams R J, Skrepnek G H, Gentry C A. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection. Journal of Clinical Pharmacy and Therapeutics. 2019; 44 : 220–228
  2. Gilligan A M, Alberts D S, Roe D J, Skrepnek G H. Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer. American Journal of Medicine. 2018; 131 : 1187-1199
  3. Pham T T, Skrepnek G H, Bond C, Alfieri T, Cothran T J, Keast S. Overview of Prescription Opioid Deaths in the Oklahoma State Medicaid Population, 2012-2016. Medical Care. 2018; 56 : 727-735
  4. Pham T T, Keast S, Farmer K, Thompson D M, Rathbun C, Nesser N J, Holderread B P, Skrepnek G H. Sustained virologic response and costs associated with direct-acting antivirals for chronic hepatitis C infection in Oklahoma Medicaid. Journal of Managed Care and Specialty Pharmacy. 2018; 24 : 664-676
1 2 3 4 > >>



Grants

1 2 3 >>
  • Allergan (PI: Keast). 2018.
  • Tribal Collaboration and Response to the Opioid Crisis in Oklahoma. 2018.
  • Otsuka (Skrepnek/Keast PI). 2018.
  • Research Fellowship. 2017.
  • Culturally Tailored Smoking Cessation in Lung Cancer Screening (CTSC-LCs) for American Indians: A Randomized Control Trial. 2016.
1 2 3 >>